Literature DB >> 8030850

Superiority of antagonic-stress composition versus nicergoline in gerontopsychiatry.

F Schneider1, R Popa, G Mihalas, P Stefanigă, I G Mihalas, R Măties, R Mateescu.   

Abstract

Nicergoline (NE)--a cerebral vasodilator with nicotinic acid esterified in its molecule--and Antagonic-Stress (AS) composition--a neurometabolic nootropic, also containing nicotinic acid but with fast and prolonged release--were evaluated in senile dementia of Alzheimer's type (SDAT), mild to moderate intensity (DSM-IV Options Book, 1991 and ICD-10, 1990 criteria). A double-blind, randomized, comparative, and parallel clinical trial was performed on 62 old people divided into 2 groups and exclusively treated with NE or AS. Psychogeriatric evaluations (Sandoz Clinical Assessment-Geriatric scale, Self-Assessment Scale-Geriatric and their subscales) and psychometric tests (digit symbol of WAIS, Wechsler Memory Scale, and Wechsler Adult Intelligence Scale-WAIS) were made before and after 3 months of treatment. Prolonged and large dose treatments with NE and AS significantly decreased the psychogeriatric scores, diminished the deterioration index, and improved cognitive performances (ANOVA). Therapeutical effects of AS were significantly higher than those of NE (ANCOVA). The better actions of AS in senile dementia and for improving cognitive function and behavior are discussed in connection with its multiple neurometabolic composition, the synergism of components, the antiischemic action of its antioxidants, its anti-free radical complementary action (deceleration of the aging rate, brain and erythrocyte lipofuscinolysis, complex antioxidative and scavenger formula), the multivitamin and multimineral supplementation and, finally, with the superiority of multitherapy vs. monotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8030850     DOI: 10.1111/j.1749-6632.1994.tb12102.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

Review 1.  Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.

Authors:  M Simard; R van Reekum
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

Review 2.  Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.

Authors:  M Fioravanti; L Flicker
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline.

Authors:  M C Morris; D A Evans; J L Bienias; P A Scherr; C C Tangney; L E Hebert; D A Bennett; R S Wilson; N Aggarwal
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

4.  The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.

Authors:  Bertrand Lebouché; Mohammad-Ali Jenabian; Joel Singer; Gina M Graziani; Kim Engler; Benoit Trottier; Réjean Thomas; Marie-Josée Brouillette; Jean-Pierre Routy
Journal:  Trials       Date:  2014-10-07       Impact factor: 2.279

Review 5.  Therapeutic use of nicergoline.

Authors:  Bengt Winblad; Mario Fioravanti; Tomas Dolezal; Inara Logina; Ivan Gospodinov Milanov; Dinu Cristian Popescu; Alina Solomon
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.